25

Society for Ambulatory Anesthesia (SAMBA)

Virtual
12-15 May 2021

04 May 2021

Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

04 May 2021

Acacia Pharma meldt vervroegde terugbetaling van lening van Hercules Technology Growth Capital

21 April 2021

Acacia Pharma Becomes New Industry Supporter of the American Society of Anesthesiologists

21 April 2021

Acacia Pharma wordt nieuwe Industry Supporter van de  American Society of Anesthesiologists

30 March 2021

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

29 March 2021

Results for the Year ended 31 December 2020

29 March 2021

Resultaten van het boekjaar eindigend op 31 december 2020

18 March 2021

Acacia Pharma publiceert op 29 maart 2021 de jaarresultaten 2020 en geeft daarbij een ‘business update'

23 February 2021

Proposed Capital Raising

19 February 2021

Acacia Pharma Group plc - Results of Placing - EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities

18 February 2021

Acacia Pharma Group plc - Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS®

18 February 2021

Wijziging van EU-lidstaat van herkomst

18 February 2021

Change of EU Home Member State

28 January 2021

Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

28 January 2021

Acacia Pharma brengt BYFAVO™ op de markt in de Verenigde Staten voor procedurele sedatie bij volwassenen die een medische ingreep ondergaan die 30 minuten of minder duurt

20 January 2021

Acacia Pharma Wins BEL Small Company of the Year for the Second Consecutive Year

20 January 2021

Acacia Pharma is voor het tweede opeenvolgende jaar uitgeroepen tot ‘BEL Small Company of the Year’

15 December 2020

Issues of New Ordinary Shares in Connection with the Byfavo™ Acquisition

15 December 2020

Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

09 October 2020

Acacia Pharma Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS® and BYFAVO™

06 October 2020

Acacia Pharma Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US

23 August 2020

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

14 August 2020

Proposed Capital Raising

14 August 2020

Acacia Pharma Prospectus: Issue of 12,500,000 New Ordinary Shares